Overcoming cancers resistant to HER-2 antibodies /
Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-H...
Guardado en:
| Otros Autores: | |
|---|---|
| Formato: | Electrónico eBook |
| Lenguaje: | inglés |
| Publicado: |
Amsterdam :
Academic Press,
2023.
|
| Colección: | Breaking tolerance to antibody-mediated immunotherapy
Breaking Tolerance to Antibody-Mediated Immunotherapy ; 2 |
| Materias: | |
| Acceso en línea: | ScienceDirect |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000cam a22000007i 4500 | ||
|---|---|---|---|
| 001 | on1450487680 | ||
| 003 | OCoLC | ||
| 005 | 20260915095213.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 240731s2023 ne o 000 0 eng d | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d OCLCO |d UKAHL |d N$T |d OCLCL | ||
| 020 | |a 0128167386 |q (electronic bk.) | ||
| 020 | |a 9780128167380 |q (electronic bk.) | ||
| 020 | |z 9780128164082 | ||
| 020 | |z 0128164085 | ||
| 035 | |a (OCoLC)1450487680 | ||
| 050 | 4 | |a RC271.I45 | |
| 082 | 0 | 4 | |a 616.99406 |2 23 |1 https://id.oclc.org/worldcat/ddc/E43YrG7877wJmjDCVdKQxQY7VH |
| 245 | 0 | 0 | |a Overcoming cancers resistant to HER-2 antibodies / |c edited by Benjamin Bonavida. |
| 264 | 1 | |a Amsterdam : |b Academic Press, |c 2023. | |
| 300 | |a 1 online resource (250 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Breaking tolerance to antibody-mediated immunotherapy | |
| 490 | 0 | |a Breaking Tolerance to Antibody-Mediated Immunotherapy ; |v 2 | |
| 520 | |a Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies. | ||
| 588 | 0 | |a Print version record. | |
| 650 | 0 | |a Cancer |x Immunotherapy. | |
| 650 | 0 | |a Drug resistance in cancer cells. | |
| 650 | 0 | |a HER-2 protein. | |
| 650 | 2 | |a Drug Resistance, Neoplasm |0 (DNLM)D019008 | |
| 650 | 6 | |a Cancer |x Immunothérapie. |0 (CaQQLa)201-0168739 | |
| 650 | 6 | |a Cellules cancéreuses |x Résistance aux médicaments. |0 (CaQQLa)201-0217335 | |
| 650 | 7 | |a Cancer |x Immunotherapy |2 fast |0 (OCoLC)fst00845386 | |
| 650 | 7 | |a Drug resistance in cancer cells |2 fast |0 (OCoLC)fst00898703 | |
| 650 | 7 | |a HER-2 protein |2 fast |0 (OCoLC)fst00949828 | |
| 700 | 1 | |a Bonavida, Benjamin, |e editor. |1 https://isni.org/isni/0000000028059910. | |
| 776 | 0 | 8 | |i Print version: |t Overcoming cancers resistant to HER-2 antibodies. |d Amsterdam : Academic Press, 2023 |z 9780128164082 |w (OCoLC)1390612227 |
| 856 | 4 | 0 | |3 ScienceDirect |u https://www.sciencedirect.com/science/book/9780128164082 |